Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cytoreduction Regimens

A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa

Bone Marrow Transplantation volume 33, pages 19–24 (2004)Cite this article

Summary:

The purpose of this study was to evaluate the efficacy and toxicity of the preparative regimen of thiotepa and etoposide in patients undergoing autologous transplantation for relapsed non-Hodgkin's lymphoma. The study involved 65 consecutive patients who underwent autologous transplantation using the thiotepa/etoposide regimen for relapsed intermediate-grade NHL at the University of Wisconsin Hospital and Clinics (UWHC) between 1987 and 2001. The regimen consisted of thiotepa 300 mg/m2/day and etoposide 700 mg/m2/day on days –6, −5, and –4. The median age at the time of transplant was 49 years. A total of 50 patients (76%) had diffuse large-cell lymphoma. A total of 50 (77%) patients had chemosensitive disease, and 15 (23%) were chemoresistant. With a median follow-up of 34 months (range, 3–163), 28 patients (43%) remain in CR and 33 (51%) have developed recurrent or progressive disease. The overall survival and event-free survival at 3 years are 40% (95% CI 26–53%) and 32% (95% CI 20–45%), respectively. There was one death attributed to regimen-related toxicity (RRT). Reversible gastrointestinal toxicity was the major RRT, and there was minimal pulmonary and cardiac toxicity. We conclude that the combination of thiotepa and etoposide is an effective preparative regimen with acceptable RRT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545 (see comments).

    Article  CAS  Google Scholar 

  2. van Besien K, Tabocoff J, Rodriguez M et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995; 15: 549–555.

    CAS  PubMed  Google Scholar 

  3. Patti C, Majolino I, Scime R et al. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 1993; 51: 18–24.

    Article  CAS  Google Scholar 

  4. Stiff PJ, Dahlberg S, Forman SJ et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens – a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48–55.

    Article  CAS  Google Scholar 

  5. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–595.

    Article  CAS  Google Scholar 

  6. Blume KG, Forman SJ . High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1992; 19: 63–66.

    CAS  PubMed  Google Scholar 

  7. Finlay JL, August C, Packer R et al. High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neurooncol 1990; 9: 239–248.

    Article  CAS  Google Scholar 

  8. Heideman RL, Cole DE, Balis F et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736–741.

    CAS  Google Scholar 

  9. Forman SJ, Blume KG, Thomas ED . Hematopoietic cell transplantation. Blackwell Science: Oxford: Malden MA, USA, 1999, p 947.

  10. Alessandrino EP, Bernasconi P, Colombo A et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309–313.

    Article  CAS  Google Scholar 

  11. Herzig RH . High-dose etoposide and marrow transplantation. Cancer 1991; 67: 292–298.

    Article  CAS  Google Scholar 

  12. de Magalhaes-Silverman M, Lister J, Rybka W et al. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997; 19: 777–781.

    Article  CAS  Google Scholar 

  13. Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case–control study. Blood 2003; 101: 2015–2023.

    Article  CAS  Google Scholar 

  14. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413.

    Article  CAS  Google Scholar 

  15. Caballero MD, Rubio V, Rifon J et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the UWHC Hematology and Bone Marrow Transplant nurses on the ward and in the clinic for their excellent and untiring care of patients. We also thank the Bone Marrow Transplant coordinators and data managers for their outstanding dedication.

Author information

Authors and Affiliations

  1. University of Wisconsin, Madison, WI, USA

    A G McCoy, E P Smith, M E Atkinson, B Baranski, B S Kahl, M Juckett, T Mitchell, R Gangnon & W L Longo

Authors
  1. A G McCoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E P Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M E Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Baranski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B S Kahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Juckett
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Gangnon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W L Longo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A G McCoy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCoy, A., Smith, E., Atkinson, M. et al. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant 33, 19–24 (2004). https://doi.org/10.1038/sj.bmt.1704312

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704312

Keywords

This article is cited by

Search

Advanced search

Quick links